Analysis of factors predicting survival in patients with hepatocellular carcinoma treated with percutaneous laser ablation

Pacella, Claudio Maurizio; Bizzarri, Giancarlo; Francica, Giampiero; Forlini, G; Petrolati, A.; Valle, D.; Anelli, Vincenzo; Bianchini, A.; Nuntis, Stefano De; Pacella, Sara; Rossi, Z.; Osborn, John; Stasi, Roberto

doi:10.1016/j.jhep.2006.01.031

Cited by 39 publications

(29 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Percutaneous laser ablation (PLA), which involves the direct deposition of laser light via fiber-optic applicators to induce tissue hyperthermia in tumors, is a recent technique that has also been proposed as an active treatment for patients with HCC [101,102,103,104]. Pacella et al [105] retrospectively analyzed the use of PLA for treating nonsurgical early HCC and showed an initial complete response in 338 patients (78%) with a median OS of 47 months.…”

Section: Other Local Ablative Techniquesmentioning

confidence: 99%

A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma

Shi

Zhai

2016

Gastrointest Tumors

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer-related deaths. Hepatic resection and liver transplantation are considered to be the preferred treatment for HCC. However, as novel therapeutic options such as image-guided locoregional therapies have emerged and been refined, the manner in which HCC is treated has changed dramatically compared with what it was considered just 2 decades earlier. Summary: This study reviews the current results of various image-guided locoregional therapies for treating HCC, especially focusing on thermal ablative and transarterial techniques. Key Message: Advances in image-guided locoregional therapies, including local ablative therapy and transarterial therapy, have led to a major breakthrough in the management of HCC. Both survival rates and cure rates of patients with HCC have improved markedly since the introduction of these techniques. Practical Implications: Radiofrequency ablation is currently considered as an alternative to surgical resection for patients with early-stage HCC. A newer technique of ablation such as microwave ablation is increasingly being used, especially for large HCC. Transarterial chemoembolization has become a standard care for asymptomatic patients with multinodular tumors in intermediate-stage disease, and transarterial radioembolization has become the method of choice in HCC cases with portal vein thrombosis. Moreover, combination treatment modalities, such as thermal-based ablation combined with transarterial chemoembolization or ¹²⁵I seed implant brachytherapy, may further broaden their clinical indications for HCC. Moreover, use of localized radiation in combination with thermal ablation has been reported to improve tumor control and long-term survival.

show abstract

Section: Other Local Ablative Techniquesmentioning

confidence: 99%

A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma

Shi

Zhai

2016

Gastrointest Tumors

View full text Add to dashboard Cite

show abstract

“…Laser ablation therapy has been used in the treatment of solid tumor of HCC (Pacella et al 2006). We first used laser ablation in the treatment of PVTT associated with hepatocellular carcinoma in 2002, with promising preliminary results (Lu et al 2004).…”

Section: Introductionmentioning

confidence: 99%

Treatment of portal vein tumor thrombus of hepatocellular carcinoma with percutaneous laser ablation

Shen

Yan

et al. 2008

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Percutaneous laser ablation (PLA) has been recently shown to be an effective technique to obtain HCC thermal ablation in patients ineligible for surgical resection [32,33]. We recently reported that PLA could provide results comparable to RFA in HCC patients waiting LT, since the rate of complete necrosis found at the post-explant analysis in nodules up to 3 cm was of 62% [34].…”

Section: Other Treatmentsmentioning

confidence: 99%

Bridge Treatments for HCC in the Waiting List for Liver Transplantation

Pompili¹,

Abbate²,

Nicolardi³

et al. 2011

TOTRANSJ

View full text Add to dashboard Cite

During the past years, several therapeutic procedures have been proposed as bridging treatments in patients with hepatocellular carcinoma waiting for liver transplantation. Resective surgery, transarterial chemoembolization, radiofrequency thermal ablation and percutaneous ethanol injection are the most experienced, with the aim to decrease the rate of drop-out from LT waiting list, and the risk of HCC recurrence after transplant. Indeed, for patients within the Milan criteria, a time on waiting list exceeding 6-12 months is a known risk factor of tumor progression and drop out. For this reason, the application of bridging treatments in these patients might be reasonable and several studies in recent years have documented their usefulness to control tumor progression before the transplant. However, the favourable impact of these treatments on post-transplant patients' survival is still under investigation and the available studies provide controversial results. Bridging therapies have also been used for the downstaging of tumors exceeding the conventional "Milan criteria". Some recent data regarding multimodal sequential therapies seem to report promising results in terms of overall and disease-free survival of treated patients attaining effective downstaging before transplant.

show abstract

Analysis of factors predicting survival in patients with hepatocellular carcinoma treated with percutaneous laser ablation

Cited by 39 publications

References 40 publications

A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma

A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma

Treatment of portal vein tumor thrombus of hepatocellular carcinoma with percutaneous laser ablation

Bridge Treatments for HCC in the Waiting List for Liver Transplantation

Contact Info

Product

Resources

About